Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2006 3
2007 3
2008 3
2009 5
2010 11
2011 12
2012 9
2013 12
2014 12
2015 17
2016 18
2017 8
2018 3
2019 9
2020 8
2021 5
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27127165

130 results

Results by year

Filters applied: . Clear all
Page 1
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T, Emi Y, Oki E, Kobayashi K, Tsuji A, Shimokawa M, Tanaka T, Akagi Y, Ogata Y, Baba H, Yoshida K, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takahashi T, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):585-93. doi: 10.1007/s00280-016-3109-4. Epub 2016 Jul 28. Cancer Chemother Pharmacol. 2016. PMID: 27468920 Clinical Trial.
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Yamada Y, et al. Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Lancet Oncol. 2013. PMID: 24225157 Clinical Trial.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. Hong YS, et al. Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10. Lancet Oncol. 2012. PMID: 23062232 Clinical Trial.
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, Lindh B, Bjerregaard JK, Glimelius B. Pfeiffer P, et al. Clin Colorectal Cancer. 2015 Sep;14(3):170-6. doi: 10.1016/j.clcc.2015.03.002. Epub 2015 Mar 25. Clin Colorectal Cancer. 2015. PMID: 25956187 Clinical Trial.
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Nishizawa Y, Haraguchi N, Kim H, Ide Y, Nakata K, Okamura S, Kudo T, Satoh T, Uemura M, Matsuda C, Mizushima T, Murata K, Doki Y, Eguchi H. Nishizawa Y, et al. BMC Cancer. 2021 Aug 23;21(1):947. doi: 10.1186/s12885-021-08690-y. BMC Cancer. 2021. PMID: 34425776 Free PMC article. Clinical Trial.
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Samura H, Oki E, Okumura H, Yoshida T, Kai S, Kobayashi K, Kinjo T, Mori S, Tohyama T, Ohgaki K, Kawanaka H, Makiyama A, Ureshino N, Kotaka M, Shimose T, Ando K, Saeki H, Baba H, Maehara Y, Mori M. Samura H, et al. Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30. Cancer Chemother Pharmacol. 2020. PMID: 32734398 Clinical Trial.
Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002).
Oki E, Emi Y, Miyamoto Y, Kabashima A, Higashi H, Ogata Y, Ikebe M, Saeki H, Tokunaga S, Shirabe K, Beppu T, Uchida S, Takatsuki M, Sakoda M, Eguchi S, Akagi Y, Kakeji Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Oki E, et al. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1067-74. doi: 10.1245/s10434-015-4771-1. Epub 2015 Sep 3. Ann Surg Oncol. 2015. PMID: 26334293 Clinical Trial.
130 results